Vera Therapeutics, Inc. Stock Price, News & Analysis

Vera Therapeutics reported ongoing progress in its Phase 2a JANUS clinical trial for atacicept, showing substantial and durable reductions in serum Gd-IgA1 levels in patients with IgA nephropathy. Key highlights include a 60% reduction in Gd-IgA1 for the 75mg dose, indicating potential for renal survival benefits. Financially, Vera posted a net loss of $7.6 million for Q3 2021, with $86.2 million in cash as of September 30, 2021. The company is advancing the Phase 2b ORIGIN study and awaits FDA feedback on its lupus nephritis development strategy.

The Phase 2a JANUS clinical trial for atacicept, conducted by Vera Therapeutics, demonstrated a significant and durable reduction in serum galactose-deficient IgA1 (Gd-IgA1) over 72 weeks in patients with IgA nephropathy (IgAN). The trial revealed that atacicept 75mg lowered serum Gd-IgA1 levels to the lowest risk quartiles, highlighting its potential to improve renal survival. These findings were presented at the American Society of Nephrology Kidney Week 2021. The company anticipates further results from the ongoing Phase 2b ORIGIN trial to clarify the implications of these reductions on renal function.

Vera Therapeutics announces the upcoming presentation of clinical data for its lead product candidate, atacicept, from the Phase 2a JANUS clinical trial in patients with IgA nephropathy (IgAN). The data will be shared during an ePoster session at the American Society of Nephrology Kidney Week 2021, held virtually from November 4-7, 2021. The presentation, titled 'Atacicept Reduces Serum Gd-IgA1 by Quartiles in IgAN Patients', will feature critical findings aimed at advancing treatments for this immunological disease.

Vera Therapeutics, Inc. (Nasdaq: VERA) will host a KOL webinar on IgA Nephropathy on September 20, 2021. The event will include presentations by experts Richard Lafayette, M.D., and Jonathan Barratt, Ph.D., focusing on the efficacy of atacicept in treating IgAN. Atacicept targets B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), with promising clinical trial data supporting its potential as a best-in-class therapy. The webinar will allow attendees to ask questions after the presentations.

Vera Therapeutics, Inc. (Nasdaq: VERA) reported its Q2 2021 financial results, highlighting significant clinical and financial advancements. They initiated the Phase 2b clinical trial named 'ORIGIN' for atacicept in IgA nephropathy patients, aiming to establish it as the first disease-modifying therapy for this condition. The company reported a net loss of $3.4 million, with cash and equivalents totaling $91.6 million as of June 30, 2021, bolstered by IPO proceeds. The management team expanded with the appointment of Sean Grant as Chief Financial Officer.

Vera Therapeutics announced the appointment of Sean Grant as Chief Financial Officer, effective immediately. With nearly 15 years in financial services, he brings expertise from CareDx and Citigroup, focusing on strategic investments and capital markets. CEO Marshall Fordyce emphasized Grant's significant experience will enhance the company's financial strategies as it develops its lead candidate atacicept, aimed at treating immunological diseases. Atacicept is expected to help patients with conditions like IgA nephropathy, addressing a market with no existing disease-modifying treatments.

Vera Therapeutics, Inc. (Nasdaq: VERA) reported its Q1 2021 financial results and corporate updates on June 24, 2021. The company initiated the Phase 2b ORIGIN clinical trial for atacicept aimed at treating IgA nephropathy. Vera raised approximately $128 million in total over nine months, including $48.4 million from its public offering in May 2021. The net loss for Q1 was $4.7 million, with cash and equivalents at approximately $49.5 million as of March 31, 2021. Key personnel appointments were made to enhance clinical and operational capabilities.

Vera Therapeutics (NASDAQ: VERA), a biotechnology firm focused on serious immunological diseases, announced participation in the Jefferies Virtual Healthcare Conference from June 1-4, 2021. The company's CEO, Marshall Fordyce, will present on June 4 at 9:00 AM PT (12:00 PM ET). A live webcast of the presentation will be available on the company's website, with a replay accessible for 90 days post-event. Vera's lead program, atacicept, targets IgA nephropathy and shows potential for other conditions like lupus nephritis.

Vera Therapeutics has priced its initial public offering (IPO) of 4,350,000 shares of Class A common stock at $11.00 per share, aiming to raise $47.85 million in gross proceeds. The offering is led by Jefferies, Cowen, and Evercore, with an option for underwriters to purchase an additional 652,500 shares. Trading on the Nasdaq under the ticker symbol VERA is expected to start on May 14, 2021, with the offering closing on May 18, 2021, pending customary conditions. Vera focuses on treatments for serious immunological diseases, notably developing atacicept for IgA nephropathy.